Piha-Paul et al. [151] published a Phase I, open-label study of temsirolimus, an mammalian target of rapamycin (mTOR) inhibitor [152], in combination with bevacizumab in pediatric patients with CNS tumors. This evidence concerns the gene MTOR and central nervous system neoplasm.